Swedish Orphan Biovitrum AB (SOBIV) experienced a share decline after U.S. regulators declined to approve the company’s experimental uncontrolled gout treatment, citing shortcomings tied to manufacturing. The stock traded down roughly 2.5% to SEK 454.5, a near 3% intraday fall that contrasted with a modest roughly 0.3% rise in Sweden’s OMX Stockholm 30 index, leaving Sobi among the weaker listings on the bourse.
The U.S. Food and Drug Administration issued a Complete Response Letter for Sobi’s biologics license application for NASP - described by the company as nanoencapsulated sirolimus plus pegadricase. In the letter, the agency requested additional information related to chemistry, manufacturing and controls and flagged deficiencies at contract manufacturing facilities. Per the company’s statement, the agency did not identify any safety or efficacy concerns regarding the therapy.
Sobi said it plans to engage directly with the FDA to review the agency’s feedback, determine the steps required for resubmission, and collaborate with its manufacturing partners to remedy the cited deficiencies. The company’s next actions will focus on addressing the manufacturing and CMC items outlined by the regulator.
NASP is an investigational infusion treatment administered once every four weeks and intended to reduce uric acid levels in adults with uncontrolled gout who remain insufficiently managed despite existing therapies. If the therapy ultimately receives approval, it would enter a market where Amgen Inc’s (AMGN) Krystexxa is currently the only medicine approved by the FDA specifically for uncontrolled gout.
Key details
- Sobi shares fell nearly 3% after the FDA issued a Complete Response Letter for NASP, citing manufacturing-related issues.
- The FDA requested additional chemistry, manufacturing and controls information and noted deficiencies at contract manufacturing facilities, but did not raise safety or efficacy concerns.
- Sobi will meet with the FDA and work with manufacturing partners to address deficiencies and plan a path to resubmission; NASP would compete with Amgen’s Krystexxa if approved.
Risks and uncertainties
- Manufacturing-related deficiencies at contract facilities could delay resubmission or approval timelines, affecting the company’s regulatory path - impacting the biopharma sector.
- The timing and outcome of planned meetings between Sobi and the FDA are uncertain; the company must resolve CMC issues before approval can proceed - relevant to markets and investors in the health-care and biotech sectors.
- Even if manufacturing issues are addressed, NASP would face competition from the only currently FDA-approved uncontrolled gout therapy, Krystexxa, which shapes the commercial landscape for Sobi - affecting pharmaceutical competitive dynamics.
The FDA’s focus on chemistry, manufacturing and controls rather than safety or efficacy narrows the regulatory questions to technical and quality assurance matters. Sobi’s immediate priorities, as stated, are dialogue with regulators and corrective actions with manufacturing partners. Investors and market participants will be watching for the company’s timetable for those discussions and any subsequent regulatory submissions.